<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9950">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686863</url>
  </required_header>
  <id_info>
    <org_study_id>RECES</org_study_id>
    <nct_id>NCT05686863</nct_id>
  </id_info>
  <brief_title>Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children</brief_title>
  <official_title>Sedative Effect and Safety of Remiazolam Combined With Low-dose Esketamine in Painless Bidirectional Endoscopy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the sedative effect and safety of remiazolam combined with small dose of&#xD;
      esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable&#xD;
      and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is planned to observe the painless two-way endoscopic examination of children in Tongji&#xD;
      Hospital affiliated to Tongji Medical College of Huazhong University of Science and&#xD;
      Technology from November 2022 to May 2023.To observe the sedative effect and safety of&#xD;
      remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in&#xD;
      children, and to provide a more reasonable and safe sedative and analgesic regimen for&#xD;
      children's gastrointestinal endoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2023</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Since propofol is white uniform emulsion, and ramazolam is colorless, clear and transparent liquid, anesthesiologists and surgeons may see the color of the study drug during operation, so this study is a single blind clinical study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation success rate</measure>
    <time_frame>Procedure (From the beginning of anesthesia to the end of examination)</time_frame>
    <description>Improved observer alertness and sedation score, MOAA/S</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>P group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>induction: Propofol 3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: propofol 5-10 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction: Remimazolam 0.2 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: Remimazolam 1-3 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>Remazolam for sedation in children undergoing bidirectional endoscopy</description>
    <arm_group_label>R group</arm_group_label>
    <other_name>Rema</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>Esketamine</description>
    <arm_group_label>P group</arm_group_label>
    <arm_group_label>R group</arm_group_label>
    <other_name>Esket</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol</description>
    <arm_group_label>P group</arm_group_label>
    <other_name>Prop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>remifentanil</description>
    <arm_group_label>P group</arm_group_label>
    <arm_group_label>R group</arm_group_label>
    <other_name>remifen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0-17;&#xD;
&#xD;
          -  ASA Class I-II;&#xD;
&#xD;
          -  Sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with high risk of stomach satiety and reflux aspiration;&#xD;
&#xD;
          -  Patients allergic to the study drug;&#xD;
&#xD;
          -  Obesity or severe malnutrition;&#xD;
&#xD;
          -  Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;&#xD;
&#xD;
          -  Hypertension without treatment;&#xD;
&#xD;
          -  Abnormal liver and kidney function (index ≥ 2 times the upper limit of normal&#xD;
             reference range);&#xD;
&#xD;
          -  Other congenital diseases or acute and chronic diseases that affect the observation of&#xD;
             curative effect;&#xD;
&#xD;
          -  Participate in other clinical studies within 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Liu, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>aijun Xu, Dr.</last_name>
    <phone>+8618627784217</phone>
    <email>ajxu@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aijun xu, Dr.</last_name>
      <phone>27-83663173</phone>
      <email>ajxu@tjh.tjmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tiantian Chu, Dr.</last_name>
      <phone>027-83663173</phone>
      <email>ttchumz@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 7, 2023</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>January 31, 2023</last_update_submitted>
  <last_update_submitted_qc>January 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>aijun xu</investigator_full_name>
    <investigator_title>Dr. aijun Xu</investigator_title>
  </responsible_party>
  <keyword>remiazolam</keyword>
  <keyword>esketamine</keyword>
  <keyword>bidirectional endoscopy</keyword>
  <keyword>children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Research data can be requested from the main researchers via email</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

